Lothian Partners 27

Lothian Partners 27 (Sarl) SICAR is a Luxembourg-based investment vehicle and an affiliate of Coller Capital, a global leader in the private equity secondary market. The entity is primarily recognized for its strategic investments in the life sciences and biotechnology sectors, having held significant stakes in clinical-stage companies such as Enobia Pharma, Topigen Pharmaceuticals, and PainCeptor Pharma. In 2015, the Kirchner Group announced the crystallization of several assets within the fund's portfolio as part of its "Successor GP" program, which focuses on managing and exiting orphaned or transition-stage investment funds. The vehicle was instrumental in providing capital for the development of therapies for metabolic bone disorders, respiratory diseases, and chronic pain before its portfolio was wound down.